Cognitive enhancers for anxiety disorders
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Cognitive behavioral therapy is an effective intervention for anxiety disorders. However, a significant number of people do not respond or only show partial response even after an adequate course of the treatment. Recent research has shown that the efficacy of the intervention can be improved by the use of cognitive enhancers that augment the core learning processes of cognitive-behavior therapy. This manuscript provides a review of the current state of cognitive enhancers for the treatment of anxiety disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888 · cited 3×
“Research on humans has identified a single nucleotide polymorphism in the BDNF gene (Val66Met) that influences hippocampal volume and hippocampal dependent memory (Egan et al., 2003; Hariri et al., 2003; Bueller et al., 2006).”
BackgroundThe Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Neurons in medial prefrontal cortex signal memory for fear extinction
Milad, M. R., & Quirk, G. J. (2002) · Nature · doi:10.1038/nature01138 · Cited by 1,836 · cited 2×
“…with significant activation of the mPFC region (Barrett, Shumake, Jones, & Gonzalez-Lima, 2003; Milad & Quirk, 2002; Milad, Vidal-Gonzalez, & Quirk, 2004) and that stimulation of the mPFC enhances extinction retention in rodents (Herry & Garcia, 2002; Milad & Quirk, 2002; Milad et al., 2004).”
BackgroundThe endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 1×
“This system has been linked to extinction learning in animal models (e.g., Chhatwal et al., 2009; Marsicano et al., 2002).”
MethodThe principal features and mechanisms of dopamine modulation in the prefrontal cortex
Seamans, J. K., & Yang, C. R. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.006 · Cited by 1,592 · cited 16×
“Therefore, D1 receptor-mediated action in the PFC appears to potentiate intense focal activity, whereas dampening the responsiveness of the local surrounding circuitry that would otherwise compete with the presently active circuit (Goldman-Rakic, Castner, Svensson, Siever, & Williams, 2004).”
BackgroundInfluentialHoffman, S. G., & Smits, J. A. J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0415 · Cited by 1,420
Self-citationRauch, S. L., Shin, L. M., & Phelps, E. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.004 · Cited by 1,397
D1 Dopamine Receptors in Prefrontal Cortex: Involvement in Working Memory
Sawaguchi, T., & Goldman-Rakic, P. S. (1991) · Science · doi:10.1126/science.1825731 · Cited by 1,364 · cited 1×
“For example, the D1 receptor in the dorsolateral prefrontal cortex appears to be critical to spatial working memory performance in monkeys (Sawaguchi and Goldman-Rakic, 1991).”
BackgroundRessler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063 · cited 3×
“These exciting findings from the animal laboratory were extended to the clinic in a placebo controlled trial by Ressler et al. (2004).”
BackgroundMethodInfluentialHariri, A. R., Goldberg, T. E., Mattay, V. S., Kolachana, B. S., Callicott, J. H., Egan, M. F., & Weinberger, D. R. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-17-06690.2003 · Cited by 1,045 · cited 3×
“Research on humans has identified a single nucleotide polymorphism in the BDNF gene (Val66Met) that influences hippocampal volume and hippocampal dependent memory (Egan et al., 2003; Hariri et al., 2003; Bueller et al., 2006).”
BackgroundClassical fear-conditioning in the anxiety disorders: a meta-analysis
Lissek, S., Powers, A. S., McClure, E. B., Phelps, E. A., Woldehawariat, G., Grillon, C., & Pine, D. S. (2005) · Behaviour Research and Therapy · doi:10.1016/j.brat.2004.10.007 · Cited by 1,034 · cited 1×
“Moreover, this type of learning is impaired in anxiety disorders (e.g., Rauch, Shin, & Phelps, 2006; Lissek et al., 2005).”
BackgroundThe role of ventromedial prefrontal cortex in the recovery of extinguished fear
Quirk, G. J., Russo, G. K., Barron, J. L., & Lebron, K. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06225.2000 · Cited by 957
Extinction of emotional learning: contribution of medial prefrontal cortex
Morgan, M. A., Romanski, L. M., & LeDoux, J. E. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90241-c · Cited by 897
Walker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Modafinil: a review of neurochemical actions and effects on cognition
Minzenberg, M. J., & Carter, C. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301534 · Cited by 713 · cited 3×
“Preclinical data suggest that modafinil can improve working memory performance in a doseand delay-dependent manner, that the processing of contextual cues is enhanced with modafinil, and that these effects may be augmented with sustained dosing regimens (for a review, see Minzenberg & Carter, 2008).”
BackgroundMethodPrefrontal mechanisms in extinction of conditioned fear
Quirk, G. J., Garcia, R., & González-Lima, F. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.010 · Cited by 682
Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala
Falls, W., Miserendino, M., & Davis, M. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-03-00854.1992 · Cited by 673
A guide to treatments that work
(2015) · Oxford Clinical Psychology · doi:10.1093/med:psych/9780195304145.001.0001 · Cited by 647
Charney, D. S. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790190025003 · Cited by 599
A Genetic Variant BDNF Polymorphism Alters Extinction Learning in Both Mouse and Human
Soliman, F., Glatt, C. E., Bath, K. G., Levita, L., Jones, R. M., Pattwell, S. S., Jing, D., Tottenham, N., Amso, D., Somerville, L. H., et al. (2010) · Science · doi:10.1126/science.1181886 · Cited by 585 · cited 1×
“Imaging research has demonstrated less ventromedial prefrontal cortical activity and greater amygdala activation in BDNFMet allele carriers (Soliman et al., 2010).”
BackgroundStress hormones and human memory function across the lifespan
Lupien, S. J., Fiocco, A., Wan, N., Maheu, F., Lord, C., Schramek, T., & Tu, M. T. (2005) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2004.08.003 · Cited by 562 · cited 1×
“…in glucocorticoids may impair memory functioning, there is evidence, from studies of both humans and laboratory animals, that acute increases in glucocorticoids can enhance emotional consolidation and extinction-based learning (for review see Lupien et al., 2005; Otto, McHugh, & Kantak, 2010).”
BackgroundAugmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder
Hofmann, S. G., Meuret, A. E., Smits, J. A. J., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.298 · Cited by 560 · cited 2×
“Subsequent studies have applied single doses of 50, 100, and 125 mg DCS, and have found this dose adequate for enhancement of exposure therapy (Guastella et al., 2008; Kushner et al., 2007; Hofmann et al., 2006; Otto et al., 2009; Wilhelm et al., 2008).”
MethodSelf-citationArnsten, A. F. T., & Goldman-Rakic, P. S. (1985) · Science · doi:10.1126/science.2999977 · Cited by 549 · cited 1×
“These effects probably occur at post-synaptic sites (Arnsten and Goldman-Rakic, 1985).”
BackgroundTargeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction
Goldman-Rakic, P., Castner, S., Svensson, T., Siever, L., & Williams, G. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1793-y · Cited by 544
A meta-analysis of treatment outcome for panic disorder
Gould, R. A., Ott, M. W., & Pollack, M. H. (1995) · Clinical Psychology Review · doi:10.1016/0272-7358(95)00048-8 · Cited by 520
Pharmacotherapy for post traumatic stress disorder (PTSD)
Stein, D. J., Ipser, J. C., Seedat, S., Sager, C., & Amos, T. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002795.pub2 · Cited by 519
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510 · cited 1×
“In summary, clinical studies provide strong evidence for a role of DCS in augmenting exposure therapy for the anxiety disorders, with evidence of a medium effect size (d = .60) for clinical populations (Norberg et al., 2008).”
BackgroundEffects of D-Cycloserine on Extinction: Translation From Preclinical to Clinical Work
Davis, M., Ressler, K., Rothbaum, B. O., & Richardson, R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.084 · Cited by 498 · cited 1×
“In response to this issue, Davis et al. (2006) have reasoned that under fear conditioning experiences, the NMDA receptors may already be saturated, and that because DCS is a partial agonist, it may have relative inhibitory effects at times of fear.”
BackgroundStewart, R. E., & Chambless, D. L. (2009) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0016032 · Cited by 483 · cited 1×
“…most effective treatment for anxiety disorders is cognitive-behavioral therapy (CBT), which is typically administered in form of 12 to 15 weekly sessions (e.g., Cape, Whittington, Buszewicz, Wallace, & Underwood, 2010; Gould, Otto, & Pollack, 1995; Hofmann & Smits, 2008; Stewart & Chambless, 2009).”
BackgroundHofmann, S. G. (2008) · Clinical Psychology Review · doi:10.1016/j.cpr.2007.04.009 · Cited by 397
Self-citationEnhancing Cannabinoid Neurotransmission Augments the Extinction of Conditioned Fear
Chhatwal, J. P., Davis, M., Maguschak, K. A., & Ressler, K. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300655 · Cited by 376
Augmentation of Behavior Therapy With d -Cycloserine for Obsessive-Compulsive Disorder
Wilhelm, S., Buhlmann, U., Tolin, D. F., Meunier, S. A., Pearlson, G. D., Reese, H. E., Cannistraro, P., Jenike, M. A., & Rauch, S. L. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050776 · Cited by 358 · cited 5×
“…M anuscript when DCS has been applied twice a week for more extended periods and using larger doses (cf. Kushner et al., 2007, Storch et al., 2010; Wilhelm et al., 2008), but there are enough design differences between studies that attribution of these effects to dosing cannot be made reliably.”
BackgroundInfluentialThe effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety
Haller, J., Bakos, N., Szirmay, M., Ledent, C., & Freund, T. F. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02192.x · Cited by 354
Guastella, A. J., Richardson, R., Lovibond, P. F., Rapee, R. M., Gaston, J. E., Mitchell, P., & Dadds, M. R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.11.011 · Cited by 326 · cited 2×
“Subsequent studies have applied single doses of 50, 100, and 125 mg DCS, and have found this dose adequate for enhancement of exposure therapy (Guastella et al., 2008; Kushner et al., 2007; Hofmann et al., 2006; Otto et al., 2009; Wilhelm et al., 2008).”
ResultModafinil as Adjunct Therapy for Daytime Sleepiness in Obstructive Sleep Apnea
PACK, A. I., BLACK, J. E., SCHWARTZ, J. R. L., & MATHESON, J. K. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.9.2103032 · Cited by 324
de la Mora, M. P., Gallegos-Cari, A., Arizmendi-García, Y., Marcellino, D., & Fuxe, K. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.10.010 · Cited by 296
Cape, J., Whittington, C., Buszewicz, M., Wallace, P., & Underwood, L. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-38 · Cited by 283
Efficacy of D-Cycloserine for Enhancing Response to Cognitive-Behavior Therapy for Panic Disorder
Otto, M. W., Tolin, D. F., Simon, N. M., Pearlson, G. D., Basden, S., Meunier, S. A., Hofmann, S. G., Eisenmenger, K., Krystal, J. H., & Pollack, M. H. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.07.036 · Cited by 251
Self-citationNikolaus, S., Antke, C., Beu, M., & Müller, H.-W. (2010) · Reviews in the Neurosciences · doi:10.1515/revneuro.2010.21.2.119 · Cited by 243
Adrenergic transmission facilitates extinction of conditional fear in mice
Cain, C. K., Blouin, A. M., & Barad, M. (2004) · Learning & Memory · doi:10.1101/lm.71504 · Cited by 215 · cited 2×
“…early rodent study, systemic administration of yohimbine hydrochloride resulted in a speeding up of extinction learning during massed exposure and successful fear extinction with spaced extinction trials, which usually yield minimal extinction learning relative to massed trials (Cain et al., 2004).”
BackgroundResultImpaired Extinction Retention in Adolescent Rats: Effects of D-Cycloserine
McCallum, J., Kim, J. H., & Richardson, R. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.92 · Cited by 198
Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications
Richardson, R., Ledgerwood, L., & Cranney, J. (2004) · Learning & Memory · doi:10.1101/lm.78204 · Cited by 185
Extinction memory is impaired in schizophrenia
Holt, D. J., Lebron-Milad, K., Milad, M. R., Rauch, S. L., Pitman, R. K., Orr, S. P., Cassidy, B. S., Walsh, J. P., & Goff, D. C. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.09.017 · Cited by 170 · cited 2×
“For example, deficits in extinction retention have been found in schizophrenia (Holt et al., 2009), and animal studies suggests that DCS may help overcome specific extinction retention deficits, at least those that occur developmentally (e.”
BackgroundGOFF, D., CATHER, C., GOTTLIEB, J., EVINS, A., WALSH, J., RAEKE, L., OTTO, M., SCHOENFELD, D., & GREEN, M. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.08.012 · Cited by 144 · cited 1×
“Furthermore, only limited and inconsistent positive findings of a single-dose application of 50 mg DCS was found for memory tasks in individuals with schizophrenia (Goff et al., 2008).”
BackgroundSelf-citationAcute exercise ameliorates reduced brain-derived neurotrophic factor in patients with panic disorder
Ströhle, A., Stoy, M., Graetz, B., Scheel, M., Wittmann, A., Gallinat, J., Lang, U. E., Dimeo, F., & Hellweg, R. (2010) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.07.013 · Cited by 135
Role of dopamine in the pathophysiology and treatment of obsessive–compulsive disorder
Koo, M.-S., Kim, E.-J., Roh, D., & Kim, C.-H. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.148 · Cited by 125
D-cycloserine facilitates context-specific fear extinction learning
Bouton, M. E., Vurbic, D., & Woods, A. M. (2008) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2008.07.003 · Cited by 118
Modafinil as Adjunct Therapy for Daytime Sleepiness in Obstructive Sleep Apnea
Schwartz, J. R. L., Hirshkowitz, M., Erman, M. K., & Schmidt-Nowara, W. (2003) · Chest · doi:10.1378/chest.124.6.2192 · Cited by 107
Caffeine dose effect on activation-induced BOLD and CBF responses
Chen, Y., & Parrish, T. B. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.03.012 · Cited by 103
Attenuated salivary cortisol secretion under cue exposure is associated with early relapse
JUNGHANNS, K., TIETZ, U., DIBBELT, L., KUETHER, M., JURTH, R., EHRENTHAL, D., BLANK, S., & BACKHAUS, J. (2005) · Alcohol and Alcoholism · doi:10.1093/alcalc/agh107 · Cited by 100
Temporal-spatial expression and novel biochemical properties of the memory-related protein KIBRA
Johannsen, S., Duning, K., Pavenstädt, H., Kremerskothen, J., & Boeckers, T. M. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.06.054 · Cited by 91
Dopamine D1 receptor binding in the striatum of patients with obsessive–compulsive disorder
Olver, J. S., O'Keefe, G., Jones, G. R., Burrows, G. D., Tochon-Danguy, H. J., Ackermann, U., Scott, A., & Norman, T. R. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.06.020 · Cited by 88
Otto, M. W., McHugh, R. K., & Kantak, K. M. (2010) · Clinical Psychology Science and Practice · doi:10.1111/j.1468-2850.2010.01198.x · Cited by 87
Cited by
Mathematics Anxiety, Working Memory, and Mathematics Performance in Secondary-School Children
Passolunghi, M. C., Caviola, S., De Agostini, R., Perin, C., & Mammarella, I. C. (2016) · Frontiers in Psychology · doi:10.3389/fpsyg.2016.00042 · Cited by 696
Fear Extinction and Relapse: State of the Art
Vervliet, B., Craske, M. G., & Hermans, D. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185542 · Cited by 671
Non-adherence and non-response in the treatment of anxiety disorders
Taylor, S., Abramowitz, J. S., & McKay, D. (2012) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2012.02.010 · Cited by 317
Gut memories: Towards a cognitive neurobiology of irritable bowel syndrome
Kennedy, P. J., Clarke, G., Quigley, E. M. M., Groeger, J. A., Dinan, T. G., & Cryan, J. F. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.07.001 · Cited by 193
Smits, J. A. J., Rosenfield, D., Otto, M. W., Powers, M. B., Hofmann, S. G., Telch, M. J., Pollack, M. H., & Tart, C. D. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.12.009 · Cited by 142
“D espite the overall strength of D-cycloserine (DCS) augmentation effects for extinction learning (1,2), there is evidence of failures to find an augmentation effect in both animal (3,4) and human (5–7) paradigms.”
Self-citation
Metadata
- Authors
- Hofmann, S. G., Smits, J. A. J., Asnaani, A., Gutner, C. A., & Otto, M. W.
- Venue
- Pharmacology Biochemistry and Behavior
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 99
- Issue
- 2
- Pages
- 275-284
- ISSN
- 0091-3057 (ISSN-L)
- OpenAlex
- W2134220810
- Cited by
- 68
- References
- 54
- FWCI
- 9.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.